Explore updates on potential GLP-1 uses and risks, including addiction treatment, bone injury concerns, and kidney disease effectiveness.

A GLP-2 drug candidate from Zealand Pharma failed to garner FDA approval as the regulatory agency asked for an additional trial to confirm the medication’s efficacy and safety. The experimental ...

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

Zealand Pharma is back with updated findings for its GLP-1/GLP-2 receptor dual agonist, finding mean body weight reductions rose to 11.6% for a higher dosing regimen after 28 weeks in a phase 1b trial ...

Researchers from Japan discover that glucagon-like peptide-2 (GLP-2) analogs can deeply and beneficially reshape the intestinal environment. Short bowel syndrome (SBS) represents one of the most ...

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...